XTL Biopharmaceuticals Ltd. XTLB
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 279.90% | 164.33% | -11.42% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 508.50% | 158.28% | -11.11% | ||
| Operating Income | -306.00% | -158.28% | 11.11% | ||
| Income Before Tax | -35.56% | -93.41% | 62.03% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 10.21% | -93.41% | 62.03% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 10.21% | -93.41% | 62.03% | ||
| EBIT | -306.00% | -158.28% | 11.11% | ||
| EBITDA | -281.53% | -- | 11.12% | ||
| EPS Basic | 40.00% | -85.71% | 64.29% | ||
| Normalized Basic EPS | -200.00% | -- | 0.00% | ||
| EPS Diluted | 0.00% | -100.00% | 57.14% | ||
| Normalized Diluted EPS | -200.00% | -- | 0.00% | ||
| Average Basic Shares Outstanding | 62.17% | 0.00% | 0.00% | ||
| Average Diluted Shares Outstanding | 62.17% | 0.00% | 0.00% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||